|
1
|
Oxenoid K and Chou JJ: A functional NMR
for membrane proteins: Dynamics, ligand binding, and allosteric
modulation. Protein Sci. 25:959–973. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Amaral MD, Farinha CM, Matos P and Botelho
HM: Investigating alternative transport of integral plasma membrane
proteins from the ER to the Golgi: Lessons from the cystic fibrosis
transmembrane conductance regulator (CFTR). Methods Mol Biol.
1459:105–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramboer E, Rogiers V, Vanhaecke T and
Vinken M: Effects of Trichostatin A on drug uptake transporters in
primary rat hepatocyte cultures. EXCLI J. 14:567–576.
2015.PubMed/NCBI
|
|
4
|
Hubeny A, Keiser M, Oswald S, Jedlitschky
G, Kroemer HK, Siegmund W and Grube M: Expression of organic anion
transporting polypeptide 1A2 in red blood cells and its potential
impact on antimalarial therapy. Drug Metab Dispos. 44:1562–1568.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pu Z, Zhang X, Chen Q, Yuan X and Xie H:
Establishment of an expression platform of OATP1B1 388GG and 521CC
genetic polymorphism and the therapeutic effect of tamoxifen in
MCF-7 cells. Oncol Rep. 33:2420–2428. 2015.PubMed/NCBI
|
|
6
|
Chae YJ, Lee KR, Lee JH, Lee W, Kim DD,
Chung SJ and Maeng HJ: Feasibility of the functional expression of
the human organic anion transporting polypeptide 1B1 (OATP1B1) and
its genetic variant 521T/C in the mouse liver. Eur J Pharm Sci.
96:28–36. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen M, Qu BX, Chen XL, Hu HH, Jiang HD,
Yu LS, Zhou Q and Zeng S: Construction of HEK293 cells stably
expressing wild-type organic anion transporting polypeptide 1B1
(OATP1B1*1a) and variant OATP1B1*1b and OATP1B1*15. Pharmazie.
71:337–339. 2016.PubMed/NCBI
|
|
8
|
Tryfonidis K, Basaran G, Bogaerts J,
Debled M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D,
Cufer T, Piccart M, et al: EORTC-Breast Cancer Group: A European
Organisation for Research and Treatment of Cancer randomized,
double-blind, placebo-controlled, multicentre phase II trial of
anastrozole in combination with gefitinib or placebo in hormone
receptor-positive advanced breast cancer (NCT00066378). Eur J
Cancer. 53:144–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li K, Ying M, Feng D, Du J, Chen S, Dan B,
Wang C and Wang Y: Brachyury promotes tamoxifen resistance in
breast cancer by targeting SIRT1. Biomed Pharmacother. 84:28–33.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lei L, Wang X, Wu XD, Wang Z, Chen ZH,
Zheng YB and Wang XJ: Association of CYP2D6*10 (c.100C>T)
polymorphisms with clinical outcome of breast cancer after
tamoxifen adjuvant endocrine therapy in Chinese population. Am J
Transl Res. 8:3585–3592. 2016.PubMed/NCBI
|
|
11
|
Chang JH, Chen J, Liu L, Messick K and Ly
J: Rifampin-mediated induction of tamoxifen metabolism in a
humanized PXR-CAR-CYP3A4/3A7-CYP2D6 mouse model. Drug Metab Dispos.
44:1736–1741. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Charoenchokthavee W, Panomvana D,
Sriuranpong V and Areepium N: Prevalence of CYP2D6*2, CYP2D6*4,
CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing
tamoxifen treatment. Breast Cancer (Dove Med Press). 8:149–155.
2016.PubMed/NCBI
|
|
13
|
Argalácsová S, Slanař O, Vítek P, Tesařová
P, Bakhouche H, Dražďáková M, Bartošová O, Zima T and Pertuželka L:
Contribution of ABCB1 and CYP2D6 genotypes to the outcome of
tamoxifen adjuvant treatment in premenopausal women with breast
cancer. Physiol Res. 64:(Suppl 4). S539–S547. 2015.PubMed/NCBI
|
|
14
|
Grzankowski KS, Szender JB,
Spring-Robinson CL, Lele SB, Odunsi KO and Frederick PJ: Evaluation
of metachronous breast and endometrial cancers: Preroutine and
postroutine adjuvant tamoxifen use. Int J Gynecol Cancer.
26:1440–1447. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin G, Zhang K, Yi L, Han Y, Xie J and Li
J: National prociency testing result of CYP2D6*10 genotyping for
adjuvant tamoxifen therapy in China. PLoS One. 11:e01623612016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Henderson SL, Teft WA and Kim RB: Profound
reduction in tamoxifen active metabolite endoxifen in a breast
cancer patient treated with rifampin prior to initiation of an
anti-TNFα biologic for ulcerative colitis: A case report. BMC
Cancer. 16:3042016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Durmus S, Lozano-Mena G, van Esch A,
Wagenaar E, van Tellingen O and Schinkel AH: Preclinical mouse
models to study human OATP1B1- and OATP1B3-mediated drug-drug
interactions in vivo. Mol Pharm. 12:4259–4269. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu XF, Zhou Y, Bi KS and Chen XH: Mixed
effects of OATP1B1, BCRP and NTCP polymorphisms on the population
pharmacokinetics of pravastatin in healthy volunteers. Xenobiotica.
46:841–849. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Riedmaier Emami A, Burt H, Abduljalil K
and Neuhoff S: More power to OATP1B1: An evaluation of sample size
in pharmacogenetic studies using a rosuvastatin PBPK model for
intestinal, hepatic, and renal transporter-mediated clearances. J
Clin Pharmacol. 56:(Suppl 7). S132–S142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rose RH, Neuhoff S, Abduljalil K, Chetty
M, Rostami-Hodjegan A and Jamei M: Application of a physiologically
based pharmacokinetic model to predict OATP1B1-related variability
in pharmacodynamics of rosuvastatin. CPT Pharmacometrics Syst
Pharmacol. 3:e1242014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ulvestad M, Skottheim IB, Jakobsen GS,
Bremer S, Molden E, Asberg A, Hjelmesæth J, Andersson TB, Sandbu R
and Christensen H: Impact of OATP1B1, MDR1, and CYP3A4 expression
in liver and intestine on interpatient pharmacokinetic variability
of atorvastatin in obese subjects. Clin Pharmacol Ther. 93:275–282.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Higgins JW, Bao JQ, Ke AB, Manro JR,
Fallon JK, Smith PC and Zamek-Gliszczynski MJ: Utility of
Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of
OATP-mediated pharmacokinetics and tissue distribution: Case
studies with pravastatin, atorvastatin, simvastatin, and
carboxydichlorofluorescein. Drug Metab Dispos. 42:182–192. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ide T, Sasaki T, Maeda K, Higuchi S,
Sugiyama Y and Ieiri I: Quantitative population pharmacokinetic
analysis of pravastatin using an enterohepatic circulation model
combined with pharmacogenomic Information on SLCO1B1 and ABCC2
polymorphisms. J Clin Pharmacol. 49:1309–1317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brenner S, Riha J, Giessrigl B, Thalhammer
T, Grusch M, Krupitza G, Stieger B and Jäger W: The effect of
organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the
antitumor activity of flavopiridol in breast cancer cells. Int J
Oncol. 46:324–332. 2015.PubMed/NCBI
|
|
25
|
Riha J, Brenner S, Böhmdorfer M, Giessrigl
B, Pignitter M, Schueller K, Thalhammer T, Stieger B, Somoza V,
Szekeres T, et al: Resveratrol and its major sulfated conjugates
are substrates of organic anion transporting polypeptides (OATPs):
Impact on growth of ZR-75-1 breast cancer cells. Mol Nutr Food Res.
58:1830–1842. 2014. View Article : Google Scholar : PubMed/NCBI
|
